BVT.13

BVT.13 is an orally active and selective PPARγ agonist with a maximal efficacy similar to that of Rosiglitazone (HY-17386) . In addition, BVT.13 exhibits antidiabetic activity in ob/ob mice[1].

Product Specifications

CAS Number

[756813-87-3]

UNSPSC

12352005

Hazard Statement

H302

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/bvt-13.html

Purity

98.44

Solubility

DMSO : 4.17 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)C1=CC(OC2=NC=CC=N2)=CC=C1NC(C3=CC=C(Cl)C=C3Cl)=O

Molecular Formula

C18H11Cl2N3O4

Molecular Weight

404.20

Precautions

H302

References & Citations

[1]Ostberg T, et al. A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects[J]. Journal of Biological Chemistry, 2004, 279 (39) : 41124-41130.